TESARO (TSRO) : Traders are bullish on TESARO (TSRO) as it has outperformed the S&P 500 by a wide margin of 11.29% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 1.43%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.36% in the last 1 week, and is up 15.03% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 4.94% and the 50-Day Moving Average is 49.82%. Tesaro, Inc. is up 125% in the last 3-month period. Year-to-Date the stock performance stands at 78.21%.
TESARO (NASDAQ:TSRO): On Fridays trading session , Opening price of the stock was $93 with an intraday high of $93.829. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $91.18. However, the stock managed to close at $93.24, a loss of 0.41% for the day. On the previous day, the stock had closed at $93.62. The total traded volume of the day was 1,357,118 shares.
TESARO, Inc. (TESARO) is oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. The Company has in-licensed and are developing three clinical-stage product candidates, rolapitant, niraparib and TSR-011. Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting (CINV); Niraparib, formerly known as MK-4827, is an orally active and potent poly (ADP-ribose) polymerase, and TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK). The Company is also developing immuno-oncology programs by entering into a collaboration and exclusive license agreement with AnaptysBio, Inc., for the discovery and development of antibodies for several specified immuno-oncology targets.